Vertex Pharmaceuticals today announced that the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) has granted consent for the expanded use of ...

Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through ...

What is the current share price of Vertex Pharmaceuticals (VRTX)? Vertex Pharmaceuticals's (VRTX) current share price is $488.25. This constitutes a price movement of 0.99% when compared to the share ...

Ultra-low-power cryogenic complementary metal oxide semiconductor (cCMOS) technology is crucial for quantum computers. This Perspective highlights the challenges of the state-of-the-art technology ...

My CF consists of two very rare genetic mutations. We had all heard of Trikafta being around the corner, but I had been told so many times that it wasn’t designed for someone with my mutations. So, ...

TRIKAFTA was first consented by Medsafe in 2021 for use in people with CF aged 6 years and older with at least one F508del mutation in the CFTR gene.

Klamath Community College’s Apprenticeship Center was recently awarded a $338,395 Energy Efficiency Training Grant from the Oregon Department of Energy (ODOE) to expand the growth of the college ...